Trademarks = 1

Forward Citations = 2

Loading Chart...

6 inventors (with patents filed for the assignee):

Ben C Askew (5 out of 52 patents)

Takeru Furuya (5 out of 29 patents)

D Scott Edwards (3 out of 12 patents)

4. Mark E Duggan (2 out of 79 patents)

5. Richard Wayne Heidebrecht, Jr (1 out of 17 patents)

6. Richard W Heidebrecht (1 out of 1 patent)

5 patents: Sort by Forward Citations

1. 12497399 - Fluorinated integrin antagonists (2025-12-16),

2. 12286432 - Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof (2025-04-29),

3. 11858900 - Fluorinated 2-amino-4-(substituted amino)phenyl carbamate derivatives (2024-01-02),

4. 11685738 - Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof (2023-06-27),

5. 11685737 - Fluorinated integrin antagonists (2023-06-27),

Company Overview

Ocuterra Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for ocular diseases. The company aims to address unmet medical needs in the field of ophthalmology through its proprietary drug candidates. Ocuterra is committed to advancing its pipeline of treatments that target various conditions affecting vision and eye health, leveraging cutting-edge research and technology to improve patient outcomes. With a team of experienced professionals in drug development and clinical research, Ocuterra is dedicated to bringing new hope to patients suffering from debilitating eye disorders.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

5 Patents

#299 in Boston, MA

#2,894 in Massachusetts

#51,644 in US

Boston, MA, United States of America

Ocuterra Therapeutics, Inc.

Forward Citations = 2

6 inventors:

Ben C Askew (5 out of 52 patents)

Takeru Furuya (5 out of 29 patents)

D Scott Edwards (3 out of 12 patents)

4. Mark E Duggan (2 out of 79 patents)

5. Richard Wayne Heidebrecht, Jr (1 out of 17 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ocuterra Therapeutics, Inc.. Retrieved from https://idiyas.com/company/ocuterra-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]